State-of-the-art overview on biological treatment for CRSwNP

Area of Science:

• Immunology
• Otolaryngology
• Pharmacology

Background:

• Severe chronic rhinosinusitis with nasal polyps (CRSwNP) often involves T helper 2 type inflammation, similar to asthma and atopic dermatitis.
• This inflammation is driven by cytokines like IL-4, IL-13, IL-5, and IgE, prompting research into targeted biological therapies.
• Biologicals are increasingly used as add-on treatments for CRSwNP, with demonstrated efficacy in various studies.

Purpose of the Study:

• To conduct a comparative analysis of biological treatments for CRSwNP using data from Phase 2 and 3 studies.
• To provide a comprehensive overview of different biologicals and their outcomes in CRSwNP treatment.
• To assess treatment efficacy based on patient-relevant and patient-irrelevant outcome parameters.

Main Methods:

• A PRISMA search identified 7 rigorous Phase 2 and 3 clinical trials for analysis.
• Included studies had clear CRSwNP definitions, multiple dosages, comparable timeframes, and consistent outcome measures.
• Effect sizes for dupilumab, mepolizumab, and omalizumab were compared for key outcomes over 16-25 weeks.

Main Results:

• Direct efficacy comparison is challenging due to study heterogeneity, but all evaluated biologicals show significant effect sizes.
• Dupilumab, mepolizumab, and omalizumab appear to substantially reduce symptom burden in patients with refractory CRSwNP.
• Dupilumab demonstrated significant effects on both patient-relevant and irrelevant measures of smell loss, aligning with clinical observations.

Conclusions:

• Despite varied trial protocols, this overview synthesizes the outcomes of biological treatments for CRSwNP.
• Further real-world registries and comparative trials are necessary to address remaining questions.
• Endotype-driven treatment strategies may offer future advancements in managing CRSwNP.